Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives

被引：17

作者：

Abou Dalle, Iman ^{[1
]}

Dulery, Remy ^{[2
]}

Moukalled, Nour ^{[1
]}

Ricard, Laure ^{[2
]}

Stocker, Nicolas ^{[2
]}

El-Cheikh, Jean ^{[1
]}

Mohty, Mohamad ^{[2
]}

Bazarbachi, Ali ^{[1
]}

机构：

[1] Amer Univ, Hematol Oncol Div, Beirut Med Ctr, Beirut, Lebanon

[2] Sorbonne Univ, AP HP, St Antoine Hosp, Dept Clin Hematol & Cellular Therapy,INSERM,UMRs 9, Paris, France

来源：

BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期

关键词：

RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA; RITUXIMAB PLUS LENALIDOMIDE; MANAGEABLE SAFETY PROFILE; CELL LYMPHOMA; SUBCUTANEOUS EPCORITAMAB; TRISPECIFIC ANTIBODY; MOSUNETUZUMAB; OUTCOMES; EFFICACY; THERAPY;

D O I：

10.1038/s41408-024-00989-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin's lymphoma (B-NHL). In the relapsed/refractory setting, salvage chemotherapy and autologous stem cell transplantation are capable of curing 50% of patients, whereas the other half will have a dismal outcome with a median overall survival of less than 12 months. This unmet need reinforced the importance of innovative therapies like the BsAbs and CAR-T cell therapies. In this review, we delve into BsAbs in B-NHL from the preclinical development to clinical data in both refractory and frontline settings, and then discuss future perspectives.

引用

页数：11

共 66 条

[1] Subcutaneous Epcoritamab plus R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results [J].

Abrisqueta, Pau ;

Cordoba, Raul ;

Falchi, Lorenzo ;

de Vos, Sven ;

Nijland, Marcel ;

Offner, Fritz ;

Wu, Jun ;

Bykhovski, Irina ;

Wang, Liwei ;

Rana, Ali ;

Phillips, Tycel .

BLOOD, 2022, 140 :1068-1069

[2] CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies [J].

Bacac, Marina ;

Colombetti, Sara ;

Herter, Sylvia ;

Sam, Johannes ;

Perro, Mario ;

Chen, Stanford ;

Bianchi, Roberta ;

Richard, Marine ;

Schoenle, Anne ;

Nicolini, Valeria ;

Diggelmann, Sarah ;

Limani, Florian ;

Schlenker, Ramona ;

Husser, Tamara ;

Richter, Wolfgang ;

Bray-French, Katharine ;

Hinton, Heather ;

Giusti, Anna Maria ;

Freimoser-Grundschober, Anne ;

Lariviere, Laurent ;

Neumann, Christiane ;

Klein, Christian ;

Umana, Pablo .

CLINICAL CANCER RESEARCH, 2018, 24 (19) :4785-4797

[3] Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial [J].

Bannerji, Rajat ;

Arnason, Jon E. ;

Advani, Ranjana H. ;

Brown, Jennifer R. ;

Allan, John N. ;

Ansell, Stephen M. ;

Barnes, Jeffrey A. ;

O'Brien, Susan M. ;

Chavez, Julio C. ;

Duell, Johannes ;

Rosenwald, Andreas ;

Crombie, Jennifer L. ;

Ufkin, Melanie ;

Li, Jingjin ;

Zhu, Min ;

Ambati, Srikanth R. ;

Chaudhry, Aafia ;

Lowy, Israel ;

Topp, Max S. .

LANCET HAEMATOLOGY, 2022, 9 (05) :E327-E339

[4] Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy [J].

Bannerji, Rajat ;

Allan, John N. ;

Arnason, Jon E. ;

Brown, Jennifer R. ;

Advani, Ranjana ;

Ansell, Stephen M. ;

O'Brien, Susan M. ;

Duell, Johannes ;

Martin, Peter ;

Joyce, Robin M. ;

Li, Jingjin ;

Flink, Dina M. ;

Zhu, Min ;

Weinreich, David M. ;

Yancopoulos, George D. ;

Sirulnik, Andres ;

Chaudhry, Aafia ;

Ambati, Srikanth R. ;

Topp, Max S. .

BLOOD, 2020, 136

[5] Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study [J].

Bartlett, Nancy L. ;

Sehn, Laurie H. ;

Matasar, Matthew J. ;

Schuster, Stephen J. ;

Assouline, Sarit ;

Giri, Pratyush ;

Kuruvilla, John ;

Canales, Miguel ;

Dietrich, Sascha ;

Fay, Keith ;

Ku, Matthew ;

Nastoupil, Loretta J. ;

Wei, Michael C. ;

Yin, Shen ;

To, Iris ;

Huang, Huang ;

Min, Juliana ;

Penuel, Elicia ;

Budde, L. Elizabeth .

BLOOD, 2022, 140 :1467-1470

[6] Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma [J].

Broeske, Ann-Marie E. ;

Korfi, Koorosh ;

Belousov, Anton ;

Wilson, Sabine ;

Ooi, Chia-Huey ;

Bolen, Christopher R. ;

Canamero, Marta ;

Alcaide, Enrique Gomez ;

James, Ian ;

Piccione, Emily C. ;

Carlile, David J. ;

Dimier, Natalie ;

Umana, Pablo ;

Bacac, Marina ;

Weisser, Martin ;

Dickinson, Michael .

BLOOD ADVANCES, 2022, 6 (03) :1025-1037

[7] Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance [J].

Brouwer-Visser, Jurriaan ;

Fiaschi, Nathalie ;

Deering, Raquel P. ;

Dhanik, Ankur ;

Cygan, Kamil J. ;

Zhang, Wen ;

Jeong, Se ;

Pourpe, Stephane ;

Boucher, Lauren ;

Hamon, Sara ;

Topp, Max S. ;

Bannerji, Rajat ;

Duell, Johannes ;

Advani, Ranjana ;

Flink, Dina M. ;

Chaudhry, Aafia ;

Sirulnik, Andres ;

Murphy, Andrew J. ;

Weinreich, David M. ;

Yancopoulos, George D. ;

Thurston, Gavin ;

Ambati, Srikanth R. ;

Jankovic, Vladimir .

BLOOD, 2020, 136

[8] A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies [J].

Budde, Elizabeth ;

Gopal, Ajay K. ;

Kim, Won Seog ;

Flinn, Ian W. ;

Cheah, Chan Yoon Y. ;

Nastoupil, Loretta ;

Matasar, Matthew J. ;

Diefenbach, Catherine S. ;

Gregory, Gareth P. ;

Qazi, Ibrahim ;

Pang, Ching-Fai ;

Leabman, Maya ;

Hernandez, Genevive ;

Sison, Iris ;

Keyt, Bruce A. ;

Chen, Daniel ;

Armand, Philippe .

BLOOD, 2021, 138

[9] Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study [J].

Budde, Lihua E. ;

Sehn, Laurie H. ;

Matasar, Matthew ;

Schuster, Stephen J. ;

Assouline, Sarit ;

Giri, Pratyush ;

Kuruvilla, John ;

Canales, Miguel ;

Dietrich, Sascha ;

Fay, Keith ;

Ku, Matthew ;

Nastoupil, Loretta ;

Cheah, Chan Yoon ;

Wei, Michael C. ;

Yin, Shen ;

Li, Chi-Chung ;

Huang, Huang ;

Kwan, Antonia ;

Penuel, Elicia ;

Bartlett, Nancy L. .

LANCET ONCOLOGY, 2022, 23 (08) :1055-1065

[10] Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study [J].

Budde, Lihua E. ;

Assouline, Sarit ;

Sehn, Laurie H. ;

Schuster, Stephen J. ;

Yoon, Sung-Soo ;

Yoon, Dok Hyun ;

Matasar, Matthew J. ;

Bosch, Francesc ;

Kim, Won Seog ;

Nastoupil, Loretta J. ;

Flinn, Ian W. ;

Shadman, Mazyar ;

Diefenbach, Catherine ;

O'Hear, Carol ;

Huang, Huang ;

Kwan, Antonia ;

Li, Chi-Chung ;

Piccione, Emily C. ;

Wei, Michael C. ;

Yin, Shen ;

Bartlett, Nancy L. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (05) :481-+

← 1 2 3 4 5 6 7 →